J&J's Drugs Get CHMP Recommendations for Blood Cancer IndicationsZacks Investment Research • 06/23/25
IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)PRNewsWire • 06/23/25
If I Could Only Buy 2 Dividend Stocks: June's Top Picks For Global DiversificationSeeking Alpha • 06/20/25
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc LawsuitBusiness Wire • 06/18/25
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?Zacks Investment Research • 06/16/25
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary diseasePRNewsWire • 06/15/25
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphomaPRNewsWire • 06/13/25
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemiaPRNewsWire • 06/12/25
Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference TranscriptSeeking Alpha • 06/11/25
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?Zacks Investment Research • 06/11/25
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritisPRNewsWire • 06/11/25
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of DirectorsBusiness Wire • 06/10/25
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?Market Watch • 06/06/25
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate CancerZacks Investment Research • 06/04/25
I have invested in dividends for 15 years—These dividend aristocrats built my passive income stream24/7 Wall Street • 06/03/25
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativityPRNewsWire • 06/03/25
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patientsPRNewsWire • 06/03/25